



**NEW ZEALAND KING SALMON INVESTMENTS LIMITED
AND SUBSIDIARIES**

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED 31 JULY 2024**

1HY25

CONTENTS

FOR THE SIX MONTHS ENDED 31 JULY 2024

	Page
Corporate directory	3
Interim consolidated statement of comprehensive income	4
Interim consolidated statement of financial position	5
Interim consolidated statement of changes in equity	6
Interim consolidated statement of cash flows	7
Notes to the interim consolidated financial statements	8

NEW ZEALAND KING SALMON INVESTMENTS LIMITED AND SUBSIDIARIES

CORPORATE DIRECTORY

BOARD OF DIRECTORS

Mark Dewdney
Independent Non-Executive Chair
Jack Lee Porus
Non-Executive Director
Paul James Steere (*Resigned 31 March 2024*)
Independent Non-Executive Director
Chiong Yong Tiong
Non-Executive Director
Catriona Macleod
Independent Non-Executive Director
Carol Chen
Non-Executive Director
Victoria Taylor
Independent Non-Executive Director
Paul Munro (*Appointed 1 March 2024*)
Independent Non-Executive Director

Audit, Finance and Risk Committee

Paul Steere (Chair) (*Resigned 31 March 2024*)
Paul Munro (Chair) (*Appointed 31 March 2024*)
Jack Porus
Mark Dewdney

People and Performance Committee

Victoria Taylor (Chair)
Jack Porus
Mark Dewdney

Health & Safety and Food Safety Committee

Catriona Macleod (Chair)
Chiong Yong Tiong
Mark Dewdney

Fish Farming Committee

Jack Porus (Chair)
Catriona Macleod
Mark Dewdney

BANKERS

The Bank of New Zealand
Deloitte Centre
Level 6, 80 Queen Street
Auckland
New Zealand

Kiwibank

Level 9, 20 Customhouse Quay
Wellington
New Zealand

AUDITOR

PricewaterhouseCoopers (PwC)
Level 4, 60 Cashel Street
Christchurch
New Zealand

LAWYERS

Chapman Tripp
Level 34, 15 Customs Street West
Auckland
New Zealand

Gascoigne Wicks

79 High Street
Blenheim
New Zealand

Duncan Cotterill

197 Bridge Street
Nelson
New Zealand

Tavendale and Partners

94 Nile Street
Nelson
New Zealand

NEW ZEALAND KING SALMON INVESTMENTS LIMITED

Ticker: NZK
Listed on the NZX Main Board and as a Foreign Exempt Listing on the ASX

NZ Company Number: 2161790

Registered Office

17 Bullen Street
Tahunanui
Nelson
New Zealand

Postal Address

PO Box 1180, Nelson 7040
New Zealand

Telephone

+64 3 548 5714

Website

www.kingsalmon.co.nz

SHARE REGISTRY

Computershare Investor
Services Limited
Level 2, 159 Hurstmere Road
Takapuna
Auckland
New Zealand
+64 9 488 8777
enquiry@computershare.co.nz

Computershare Investor

Services Pty Limited
Yarra Fall
452 Johnston Street
Abbotsford VIC 3001
Australia
+61 3 9415 4083
enquiry@computershare.co.nz

Investor Relations

investor@kingsalmon.co.nz

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 31 JULY 2024

	Note	UNAUDITED 31 July 2024 \$000	UNAUDITED 31 July 2023 \$000
Revenue from contracts with customers	14	101,718	91,561
Cost of goods sold	6	(100,454)	(84,435)
Fair value gain on biological transformation	7	33,984	31,189
Freight costs to market		(10,638)	(11,205)
Gross profit		24,610	27,110
Other income		3,098	3,974
Sales, marketing and advertising expenses		(6,400)	(5,229)
Distribution overheads		(1,958)	(1,675)
Corporate expenses		(6,813)	(5,721)
Other expenses		(56)	-
Profit/(loss) before interest, tax, depreciation and amortisation		12,481	18,459
Depreciation and amortisation expense		(3,725)	(3,852)
Finance income		644	457
Finance expenses		(250)	(183)
Profit/(loss) before tax		9,150	14,881
Income tax credit / (expense)		(3,144)	(4,251)
Profit/(loss) after tax		6,006	10,630
Other comprehensive income			
<i>Other comprehensive income that may be reclassified to profit or loss in subsequent periods:</i>			
Exchange differences on translation of foreign operations		418	175
Movement on cash flow hedges		(1,908)	(2,687)
Release of early closed out foreign exchange contracts		(2,623)	(3,551)
Deferred tax on early closed out foreign exchange contracts		734	994
Income tax effect of movement on cash flow hedges		544	747
Net other comprehensive income / (loss)		(2,835)	(4,322)
Total comprehensive income		3,171	6,308

		UNAUDITED 31 July 2024	UNAUDITED 31 July 2023
Earnings per share			
Basic earnings per share	4	\$ 0.01	\$ 0.02
Diluted earnings per share	4	\$ 0.01	\$ 0.02

The above interim consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 JULY 2024

		UNAUDITED 31 July 2024	AUDITED 31 January 2024
	Note	\$'000	\$'000
Assets			
Current Assets			
Cash and cash equivalents		28,298	20,908
Trade and other receivables	5	18,146	18,427
Other financial assets	10	7,000	6,000
Inventories	6	35,563	37,059
Biological assets	7	80,801	82,468
Derivative financial assets	10	1,221	976
Total Current Assets		171,029	165,838
Non-current Assets			
Property, plant and equipment		50,686	48,335
Biological assets	7	9,242	11,992
Derivative financial assets	10	1,344	2,829
Intangible assets		2,979	3,282
Right-of-use assets		6,118	6,669
Total Non-current Assets		70,369	73,107
Total Assets		241,398	238,945
Liabilities			
Current Liabilities			
Trade and other payables	9	16,610	16,536
Employee benefits		3,662	3,974
Borrowings	8	1,131	3,417
Lease liabilities		994	1,028
Other financial liabilities	13	404	288
Derivative financial liabilities	10	4,483	3,639
Taxation payable		1,902	732
Total Current Liabilities		29,186	29,614
Non-current Liabilities			
Employee benefits		533	472
Borrowings	8	2,000	2,000
Lease liabilities		5,395	5,872
Deferred tax liabilities		7,886	7,741
Derivative financial liabilities	10	2,808	2,951
Total Non-current Liabilities		18,622	19,036
Total Liabilities		47,808	48,650
Net Assets		193,590	190,295
Equity			
Share capital	12	180,143	180,143
Reserves		(1,351)	1,360
Retained earnings		14,798	8,792
Total Equity		193,590	190,295

The above interim consolidated statement of financial position should be read in conjunction with the accompanying notes.

For and on behalf of the Board, who authorised the issue of these financial statements on 23 September 2024



Director

23 September 2024



Director

23 September 2024

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 31 JULY 2024

	Share Capital \$000	Foreign Currency Translation Reserve \$000	Hedge Reserve \$000	Share Based Payment Reserve \$000	Retained Earnings/ (Deficit) \$000	Total Equity \$000
UNAUDITED						
Balance as at 1 February 2024	180,143	(632)	1,375	617	8,792	190,295
Profit / (loss) for the period	-	-	-	-	6,006	6,006
Other comprehensive income / (loss)	-	418	(3,253)	-	-	(2,835)
Total comprehensive income/(loss) for the period	-	418	(3,253)	-	6,006	3,171
Share based payment expense	-	-	-	124	-	124
Balance as at 31 July 2024	180,143	(214)	(1,878)	741	14,798	193,590
UNAUDITED						
Balance as at 1 February 2023	180,143	(614)	7,209	828	(19,660)	167,906
Profit / (loss) for the period	-	-	-	-	10,630	10,630
Other comprehensive income / (loss)	-	175	(4,497)	-	-	(4,322)
Total comprehensive income/(loss) for the period	-	175	(4,497)	-	10,630	6,308
Share based payment expense	-	-	-	18	-	18
Balance as at 31 July 2023	180,143	(439)	2,712	846	(9,030)	174,232

The above interim consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED 31 JULY 2024

	UNAUDITED 31 July 2024 \$000	UNAUDITED 31 July 2023 \$000
Operating activities		
Receipts from customers	101,049	92,282
Payments to suppliers	(62,118)	(61,118)
Payments to employees	(22,626)	(19,849)
Interest received	644	457
Interest paid	(230)	(126)
Government grants received	33	99
Income tax (paid) / received	(548)	23
Net cash flows (used in) / from operating activities	16,204	11,768
Investing activities		
Placement of short term deposits	(1,000)	-
Proceeds from sale of property, plant and equipment	2	17
Purchase of property, plant and equipment	(5,212)	(1,573)
Purchase of intangible assets	-	(129)
Net cash flow (used in) / from investing activities	(6,210)	(1,685)
Financing activities		
Repayment of borrowings	(2,286)	-
Payment of lease liabilities	(517)	(726)
Net cash flows (used in) / from financing activities	(2,803)	(726)
Net increase / (decrease) in cash and cash equivalents	7,191	9,357
Net foreign exchange difference	199	88
Cash and cash equivalents at 1 February	20,908	19,221
Cash and cash equivalents at 31 July	28,298	28,666

The above interim consolidated statement of cash flows should be read in conjunction with the accompanying notes.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 31 JULY 2024

1. CORPORATE INFORMATION

The condensed interim consolidated financial statements of New Zealand King Salmon Investments Limited (the Company) and its subsidiaries (together the Group) for the six months ended 31 July 2024 were authorised by the Directors on 23 September 2024.

New Zealand King Salmon Investments Limited is a profit-orientated company incorporated and domiciled in New Zealand. The Company is registered under the Companies Act 1993 and listed on the NZX Main Board ("NZX") and the Australian Securities Exchange ("ASX"). The Company is an FMC reporting entity under the Financial Markets Conduct Act 2013.

The Group is principally engaged in the farming, processing and sale of premium salmon products.

2. BASIS OF PREPARATION

The condensed interim consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Practice in New Zealand (NZ GAAP) as appropriate for interim financial statements. They have been prepared in accordance with NZ IAS 34 *Interim Financial Reporting*. The interim financial statements and the comparative information for the six months ended 31 July 2023 are unaudited. The comparative information for the year ended 31 January 2024 is audited.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements as at 31 January 2024.

3. NEW STANDARDS, INTERPRETATIONS, AND AMENDMENTS ADOPTED BY THE GROUP

The accounting policies adopted in the interim condensed financial statements are consistent with those applied in the annual financial statements as at 31 January 2024. Management have applied the same principles and used the same key sources of estimation in the preparation of the interim financial statements as those applied in the consolidated financial statements for the period ended 31 January 2024. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 31 JULY 2024

4. EARNINGS PER SHARE

Basic earnings per share amounts are calculated by dividing the profit for the period attributable to shareholders of the Company by the weighted average number of ordinary shares on issue during the period. Diluted earnings per share are calculated by dividing the profit attributable to shareholders of the Company by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of shares that would be issued on conversion of all dilutive potential ordinary shares into ordinary shares.

	UNAUDITED 31 July 2024 \$000	UNAUDITED 31 July 2023 \$000
Earnings per share		
Profit / (Loss) attributable to ordinary equity holders	6,006	10,630
	# of Shares 000	# of Shares 000
Weighted average number of ordinary shares for basic and diluted earnings per share	538,686	541,455
Basic earnings per share	\$0.01	\$0.02
Diluted earnings per share	\$0.01	\$0.02

5. TRADE AND OTHER RECEIVABLES

	UNAUDITED 31 July 2024 \$000	AUDITED 31 January 2024 \$000
Trade and other receivables		
Trade receivables	15,677	13,968
Allowance for expected credit losses	(222)	-
Prepayments	1,599	2,991
GST receivable	990	1,455
Other receivables	102	13
Total trade and other receivables	18,146	18,427

6. INVENTORIES

	UNAUDITED 31 July 2024 \$000	AUDITED 31 January 2024 \$000
Inventories		
Raw materials	9,904	11,995
Work in progress	586	1,816
Finished goods	25,073	23,248
Total inventories	35,563	37,059

The carrying value of finished goods as at 31 January 2024 includes a fair value uplift at point of harvest of \$7,817k (31 January 2024: \$8,326k) and net realisable value provision of \$3,779k (31 January 2024: \$5,066k).

	UNAUDITED 31 July 2024 \$000	UNAUDITED 31 July 2023 \$000
Amount of inventories recognised as an expense in the statement of comprehensive income		
Cost of inventories recognised as an expense	101,902	86,148
Movement in net realisable value provision	(1,448)	(1,713)
Total cost of goods sold including fair value uplift at point of harvest	100,454	84,435

The cost of inventories recognised as an expense for the period ended 31 July 2024 includes a fair value uplift at point of harvest of \$38,565k (31 July 2023: \$27,510k). This cost is included in cost of goods sold in the Statement of Comprehensive Income.

The cost of inventory includes fish harvested at the fair value less cost to sell at harvest date, based on management's expected future sales pricing and mix of product ("deemed cost"). As at 31 July 2024 no volumes were forecasted to be sold at returns materially below deemed cost plus further manufacturing costs.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 31 JULY 2024

7. BIOLOGICAL ASSETS

The Group has two hatcheries in the South Island and six operational marine salmon farms in the Marlborough Sounds. The fish livestock typically grow for up to 31 months before harvest.

UNAUDITED	Cost	Value Gain	Total
Biological assets	\$000	\$000	\$000
As at 1 February 2024	49,692	44,768	94,460
Increase due to biological transformation ¹	43,136	31,594	74,730
Decrease due to harvest ²	(34,938)	(38,056)	(72,994)
Decrease due to mortality ³	(8,544)	-	(8,544)
Changes in fair value ⁴	-	2,390	2,390
As at 31 July 2024	49,346	40,696	90,042

UNAUDITED	Cost	Value Gain	Total
Biological assets	\$000	\$000	\$000
As at 1 February 2023	42,881	29,811	72,692
Increase due to biological transformation ¹	41,869	28,719	70,588
Decrease due to harvest ²	(30,874)	(26,561)	(57,435)
Decrease due to mortality ³	(7,806)	-	(7,806)
Changes in fair value ⁴	-	2,471	2,471
As at 31 July 2023	46,070	34,440	80,510

AUDITED	Cost	Value Gain	Total
Biological assets	\$000	\$000	\$000
As at 1 February 2023	42,881	29,811	72,692
Increase due to biological transformation ¹	85,949	59,597	145,546
Decrease due to harvest ²	(66,510)	(55,330)	(121,840)
Decrease due to mortality ³	(12,628)	-	(12,628)
Changes in fair value ⁴	-	10,690	10,690
As at 31 January 2024	49,692	44,768	94,460

¹ Biological transformation fair value is impacted by volume increases and fish weight at reporting date relative to the target harvest weight of 4 kgs (proportional recognition).

² Harvested fair value is included under cost of goods sold in the statement of comprehensive income and is calculated by multiplying the current period's harvest (biomass) by the prior years expected gross margin per kg (recognised at 100%).

³ Mortality cost is expensed directly to the statement of comprehensive income within the cost of goods sold in the period which it occurs and is not subject to a fair value uplift.

⁴ Changes in fair value are impacted by movements in margin primarily being changes in sales price and costs to sell (fish cost, harvest, processing and freight to market).

	UNAUDITED	UNAUDITED
	31 July 2024	31 July 2023
	\$000	\$000
Fair value gain / (loss) recognised in profit and loss		
Gain arising from growth of biological assets	31,594	28,719
Movement in fair value of biological assets	2,390	2,470
Total fair value gain on biological transformation	33,984	31,189

	UNAUDITED	AUDITED
	31 July 2024	31 January 2024
	\$000	\$000
Biological assets		
Current	80,801	82,468
Non-current	9,242	11,992
Total biological assets	90,043	94,460

	UNAUDITED	UNAUDITED
	31 July 2024	31 July 2023
	tonnes	tonnes
Harvested biomass		
Total live weight harvested for the period	3,820	3,401

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 31 JULY 2024

7. BIOLOGICAL ASSETS (CONTINUED)

	UNAUDITED 31 July 2024	AUDITED 31 January 2024
	tonnes	tonnes
Estimated closing biomass		
Closing fresh water stocks	107	176
Closing seawater stocks	4,458	5,203
Total estimated closing biomass live weight	4,565	5,379

Fair value measurement

Measurement of fair value is performed using a fair value model. The method of valuation therefore falls into level three of the fair value hierarchy as the inputs are unobservable inputs.

The valuation of biological assets is carried out separately for each site at a brood and strategy level. Estimated actual cost up to the date of harvest per site is used to measure the expected margin at the time the fish is defined as ready for harvest, being 4.0kg live weight. Selling price is estimated at balance date based on the most relevant future market price at expected harvest date. The expected gross margin is recognised proportionately based on average biomass at reporting date. Fair value measurement commences at the date of transfer to sea water as this is considered the point at which the fish commence their grow out cycle.

Fair value risk and sensitivity

The Group is exposed to financial risks relating to the production of salmon stock including increasing climate change volatility, climatic events, disease and contamination of water space.

The Group seeks to produce and market the highest quality salmon products. Extensive monitoring and benchmarking is carried out to provide optimum conditions and diets to maximise fish performance during the grow out cycle. Sales are maintained in a range of brands, products and markets to maximise returns from the quality mix of fish harvested. The Group has insurance to cover some of the risks relating to the livestock.

The estimated unrealised fair value gain in livestock at 31 July 2024 has decreased due to an increased forecast cost of fish harvested alongside less biomass on hand at balance date. Average price increases are forecast with continuing robust global demand for the product and rising costs of inputs. Changes in these assumptions will impact the fair value calculation. The realised profit which is achieved on the sale of inventory will differ from the calculations of fair value of biological assets because of changes in key factors such as the final market destinations and product mix of inventory sold, changes in price, foreign exchange rates, harvest weight, growth rates, mortality, cost levels and differences in harvested fish quality.

Leaving all other variables constant a 15% increase/decrease in average future sales prices would increase/decrease the fair value of biological assets on hand and profit before tax by \$17.8m (31 January 2024: \$18.3m) (excludes the impact of finished goods), while a 15% increase/decrease in future harvest volume would increase/decrease the fair value of biological assets on hand and profit before tax by \$6.2m (31 January 2024: \$6.8m).

A 15% increase/decrease in costs to sell would decrease/increase the fair value of biological assets on hand and profit before tax by \$11.6m (31 January 2024: \$11.5m). Changes in fish health and environmental factors may affect the quality of harvested fish, which may be reflected in realised profit via both achieved sales price and production costs.

8. INTEREST BEARING LOANS AND BORROWINGS

	UNAUDITED 31 July 2024	AUDITED 31 January 2024
	\$000	\$000
Current interest bearing loans and borrowings		
Secured bank loans	750	750
Other borrowings	381	2,667
Total current interest bearing loans and borrowings	1,131	3,417
Non-current interest bearing loans and borrowings		
Secured bank loans	2,000	2,000
Total non-current interest bearing loans and borrowings	2,000	2,000

The Company retains the Business Finance Scheme Loan via BNZ (expiry October 2025) that arose from the Government providing financial assistance following the Covid-19 pandemic. At 31 July 2024 the balance drawn on the Business Finance Scheme was \$2.75m (31 January 2024: \$2.75m).

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 31 JULY 2024

9. TRADE AND OTHER PAYABLES

	UNAUDITED 31 July 2024	AUDITED 31 January 2024
	\$000	\$000
Trade payables	11,114	15,480
Other payables	5,496	1,056
Total trade and other payables	16,610	16,536

10. FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying value of cash and short term deposits, trade receivables, trade payables and other current liabilities is considered a reasonable approximation to their fair value due to the short term maturities of these instruments.

The carrying value of the Business Finance Scheme Loan via BNZ is \$2.75m (31 January 2024: \$2.75m) and is considered a reasonable approximation of its fair value due to the short term maturities of the drawings.

The following financial instruments of the Group are carried at fair value:

	UNAUDITED 31 July 2024	AUDITED 31 January 2024
	\$000	\$000
Current derivative financial assets		
Forward exchange contracts	681	534
Foreign exchange options	540	442
Total current derivative financial assets	1,221	976
Current other financial assets		
Term deposits (4 -12 month term)	7,000	6,000
Total other current financial assets	7,000	6,000
Non-current derivative financial assets		
Forward exchange contracts	421	1,324
Foreign exchange options	923	1,505
Total non-current derivative financial assets	1,344	2,829
Current derivative financial liabilities		
Forward exchange contracts	2,664	1,888
Foreign exchange options	1,819	1,751
Total current derivative financial liabilities	4,483	3,639
Non-current derivative financial liabilities		
Forward exchange contracts	916	632
Foreign exchange options	1,892	2,319
Total non-current derivative financial liabilities	2,808	2,951

Valuation methods

Financial instruments have been categorised into the following hierarchy and valued according to the following definitions, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1: Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices)

Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs)

All derivative financial instruments for which a fair value is recognised have been categorised within level 2 of the fair value hierarchy. Industry experts have provided the fair values for all derivatives based on an industry standard model. There were no transfers between Level 1 and Level 2 during the period ended 31 July 2024 (31 July 2023 - nil).

11. COMMITMENTS AND CONTINGENCIES

Capital commitments

The Group has entered into agreements to purchase plant and equipment. As at 31 July 2024 the total commitment is \$3,417k (31 July 2023: \$463k).

Guarantees

The group has two guarantee facilities at 31 July 2024 totalling \$134k (31 July 2023: Three guarantee facilities totalling \$132k).

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 31 JULY 2024

12. CAPITAL AND RESERVES

	UNAUDITED	AUDITED
	31 July 2024	31 January 2024
	000	000
Share capital		
Issued shares		
Ordinary shares	538,183	541,455
Total issued shares	538,183	541,455

Ordinary shares are fully paid with no par value. Each ordinary share has an equal right to vote, to participate in dividends and to share in any surplus on winding up of the Company. No dividend was declared nor paid during the 6 months to 31 July 2024 (6 months to 31 July 2023: No dividend was declared or paid). During the period the company has acquired and cancelled 3,272,437 ordinary shares originally acquired under long term incentive plans, to enable repayment of a loan owed by Mr Rosewarne to NZK, as part of his long term incentive plans.

	# of Shares		Share Capital	
	UNAUDITED	AUDITED	UNAUDITED	AUDITED
	31 July 2024	31 January 2024	31 July 2024	31 January 2024
	000	000	\$000	\$000
Movement in ordinary share capital				
The beginning of the period	541,455	541,455	180,143	180,143
Share issue	-	-	-	-
Cancellation of shares	(3,272)	-	-	-
Total Share capital as at period end	538,183	541,455	180,143	180,143

Reserves

Foreign currency translation reserve

The foreign currency translation reserve is used to record exchange difference arising from the translation of the financial statements of the foreign subsidiary.

Hedge reserve

The hedge reserve represents the unrealised gains and losses on interest rate swaps and foreign currency forward contracts that the Group has taken out in order to mitigate foreign currency risks, net of deferred tax. Also included are the realised gains on early closed foreign currency forward contracts where the hedged future cash flows are still expected to occur (net of tax).

	UNAUDITED	AUDITED
	31 July 2024	31 January 2024
	\$000	\$000
Unrealised gain / (loss)	1,364	990
Total gain / (loss) on hedge reserves	1,364	990

Retained earnings

Retained earnings represents the profits retained in the business.

Share based payment reserve

The share based payment reserve relates to two long term incentive (LTI) schemes and two employee share ownership schemes. One of the LTI schemes was established in 2024 and relates to the grant of Performance Share Rights to eligible senior employees. The other schemes involve the Company making interest-free limited recourse loans to selected personnel to acquire shares in the Company. The employees must remain in employment for the duration of the vesting or escrow periods before the employees receive the full benefit of share ownership subsequent to repayment of the loan balance remaining at time of vesting.

13. RELATED PARTY DISCLOSURES

Subsidiaries

New Zealand King Salmon Investments Limited has the following trading subsidiaries.

Subsidiary	Country of Incorporation	Equity Interest
The New Zealand King Salmon Co. Limited	New Zealand	100%
New Zealand King Salmon Exports Limited	New Zealand	100%
The New Zealand King Salmon Pty Limited	Australia	100%
New Zealand King Salmon USA Incorporated	United States of America	100%

The principal activity of The New Zealand King Salmon Co Limited is the farming and processing of salmon. The activity of New Zealand King Salmon Exports Limited, The New Zealand King Salmon Pty Limited, and New Zealand King Salmon USA Incorporated is the distribution of salmon

At 31 July 2024 Oregon Group Limited owned 39.79% (31 July 2023: 39.55%) and China Resources Enterprise Limited owned 9.87% (31 July 2023: 9.81%) of the shares in New Zealand King Salmon Investments Limited.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 31 JULY 2024

13. RELATED PARTY DISCLOSURES (CONTINUED)

Transactions with related parties

The following provides the total amount of transactions that were entered into with related parties for the relevant financial period:

	UNAUDITED 31 July 2024	UNAUDITED 31 July 2023
	\$000	\$000
Related party payments		
Goods and services purchased from other related parties	-	-
Directors fees	180	241
Total related party payments	180	241
Related party sales	\$000	\$000
Goods sold to related parties ¹	1,739	1,783
Total related party sales	1,739	1,783
	UNAUDITED	AUDITED
	31 July 2024	31 January 2024
	\$000	\$000
Amounts owing to related parties		
Current amounts owing to related parties		
Other amounts owing to related parties	237	233
Fees payable to directors	167	55
Total current amounts owing to related parties	404	288
	\$000	\$000
Amounts owing by related parties		
Amounts owing by related parties	156	72
Total amounts owing by related parties	156	72

¹

During the period NZKS sold King Salmon to China through China Resources Food Supply Chain Co. Ltd., 40% owned by China Resources Enterprise Limited who is a shareholder of NZKS. These sales were conducted on the same terms as an arm's length transaction.

14. DISAGGREGATION OF REVENUE

	UNAUDITED 31 July 2024	UNAUDITED 31 July 2023
	\$000	\$000
Revenue by Product Group		
Whole Fish	53,716	46,443
Fillets, Steaks & Portions	24,342	21,775
Wood Roasted	3,342	3,181
Cold Smoked	12,728	12,585
Other	7,590	7,577
Total revenue by product group	101,718	91,561
	UNAUDITED	UNAUDITED
	31 July 2024	31 July 2023
	\$000	\$000
Revenue by Brand		
Ōra King	38,736	26,553
Regal	22,576	14,650
Southern Ocean	2,356	3,662
Omega Plus	1,365	1,831
New Zealand King Salmon	36,685	44,865
Total revenue by brand	101,718	91,561
	UNAUDITED	UNAUDITED
	31 July 2024	31 July 2023
	\$000	\$000
Revenue by Market		
New Zealand	33,660	31,131
North America	44,469	37,540
Australia	10,943	10,987
Japan	2,061	2,747
Europe	2,913	2,747
Other	7,672	6,409
Total revenue by geographical location of customers	101,718	91,561

Sales net of settlement discounts to two major customer for the period 1 February 2024 to 31 July 2024 totalled \$22.7m or 22.4% of total gross revenue (For the six months to 31 July 2023 two major customer totalled \$20.0m or 21.9% of total gross revenue).

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 31 JULY 2024

15. EVENTS AFTER BALANCE DATE

Dividend

No dividend was declared in respect of the 6 months ended 31 July 2024 (6 month period to 31 July 2023: Nil).